Stoke Therapeutics, Inc. 4

Thomas McCauley, CSO of Stoke Therapeutics, received a stock option award for 225,000 shares of common stock at a $29.91 exercise price on July 15, 2026.

On July 15, 2026, Thomas McCauley, Chief Scientific Officer of Stoke Therapeutics, Inc., received a stock option award for 225,000 shares of common stock with an exercise price of $29.91 per share. This is a compensatory grant classified as an acquisition of derivative securities (stock options) rather than an open-market transaction. The options have a 10-year term expiring on July 14, 2036, and they vest as to 25% of the total award on July 15, 2027, with the remaining 75% vesting in equal monthly installments over the following 36 months, contingent on his continued service. Following this grant, McCauley holds derivative securities representing rights to acquire 225,000 shares of the company’s common stock, with an aggregate notional value of approximately $6.73 million based on the $29.91 exercise price as a reference point.

Filing Facts

CIK

1623526

Ticker

STOK

Form

4

Source Type

fda

Accession

0001858760-26-000008

Alert Tier

7